List view / Grid view

Regeneron Pharmaceuticals

Filter the results



EMA to review Sanofi and Regeneron’s dermatitis drug application

13 December 2016 | By Niamh Louise Marriott, Digital Editor

The European Medicines Agency (EMA) has accepted for review the marketing authorisation application for Sanofi and Regeneron’s Dupixent (dupilumab) for the treatment of adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.


Success for Regeneron and Sanofi’s atopic dermatitis trial

5 October 2016 | By Niamh Louise Marriott, Digital Content Producer

Regeneron Pharmaceuticals and Sanofi’s two placebo-controlled Phase 3 trials, evaluating dupixent (dupilumab) in adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD), met their primary endpoints evaluating the extent and severity of the disease.


Sanofi and Regeneron announce EMA acceptance for review of Marketing Authorisation Application for sarilumab

1 August 2016 | By Sanofi / Regeneron Pharmaceuticals, Inc.

Sanofi and Regeneron Pharmaceuticals, Inc. have announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for sarilumab, an investigational human monoclonal antibody directed against the IL-6 receptor that is intended for the treatment of adult patients with moderately to severely active rheumatoid arthritis...